American Society of Hematology: Stem Cell Transplant Offers No Additional Benefit for Patients With Mantle Cell Lymphoma in Deep Remission
December 11, 2024
December 11, 2024
WASHINGTON, Dec. 11 (TNSres) -- The American Society of Hematology issued the following news release:
* * *
Transplant shows no difference in overall or progression-free survival compared with maintenance therapy alone
LBA-6: Lack of Benefit of Autologous Hematopoietic Cell Transplantation (auto-HCT) in Mantle Cell Lymphoma (MCL) Patients (pts) in First Complete Remission (CR) with Undetectable Minimal Residual Disease (uMRD): Initial Report from the ECOG-A . . .
* * *
Transplant shows no difference in overall or progression-free survival compared with maintenance therapy alone
LBA-6: Lack of Benefit of Autologous Hematopoietic Cell Transplantation (auto-HCT) in Mantle Cell Lymphoma (MCL) Patients (pts) in First Complete Remission (CR) with Undetectable Minimal Residual Disease (uMRD): Initial Report from the ECOG-A . . .